Q2 2024 Earnings Estimate for bluebird bio, Inc. (NASDAQ:BLUE) Issued By William Blair

bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at William Blair cut their Q2 2024 EPS estimates for bluebird bio in a note issued to investors on Wednesday, August 14th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings per share of ($0.63) for the quarter, down from their previous forecast of ($0.55). The consensus estimate for bluebird bio’s current full-year earnings is ($1.68) per share. William Blair also issued estimates for bluebird bio’s Q3 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.48) EPS, FY2024 earnings at ($2.29) EPS, Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($1.06) EPS.

BLUE has been the subject of a number of other reports. Barclays reduced their target price on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 target price on shares of bluebird bio in a research note on Thursday, August 15th. Bank of America reduced their target price on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Robert W. Baird reduced their price objective on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Finally, JPMorgan Chase & Co. lowered shares of bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $4.74.

bluebird bio Stock Performance

Shares of BLUE opened at $0.66 on Monday. The company’s 50 day moving average price is $1.01 and its 200 day moving average price is $1.09. bluebird bio has a 52 week low of $0.65 and a 52 week high of $5.53. The company has a market capitalization of $72.41 million, a PE ratio of -0.90 and a beta of 0.81.

Institutional Investors Weigh In On bluebird bio

Large investors have recently modified their holdings of the stock. Ghisallo Capital Management LLC bought a new stake in bluebird bio during the 4th quarter worth approximately $4,347,000. Vestal Point Capital LP bought a new stake in bluebird bio during the 4th quarter worth approximately $2,967,000. Vanguard Group Inc. grew its position in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after acquiring an additional 1,723,081 shares during the last quarter. HBK Investments L P bought a new stake in bluebird bio during the 4th quarter worth approximately $2,070,000. Finally, AQR Capital Management LLC grew its position in bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after acquiring an additional 1,013,144 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.